Other
Neoplasm by Morphology
CI-CAN-00000002Explore in graph →
Non-malignant13,328 active trials222 approved drugs2,775 evidence items
- NCIt
- C4741
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000002Explore in graph →
Clinical trials
52,686 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06840548 | A Study to Evaluate the Safety and Dosimetry of 68Ga-OncoCAIX in Patients With CAIX-positive Cancer(OncoCAIX) | completed | Phase 1 | 20 | Philogen S.p.A.INDUSTRY | 1 | Jan 13, 2026 | clinicaltrials |
| NCT05337137 | A Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver Cancer(RELATIVITY-106) | completed | Phase 1 / Phase 2 | 83 | Bristol-Myers SquibbINDUSTRY | 15 | Jan 12, 2026 |
| clinicaltrials |
| NCT06558513 | To Evaluate a Phase I/II Clinical Study of XNW5004 Tablets in Patients With Relapsed/Refractory Advanced Tumors | completed | Phase 1 / Phase 2 | 120 | Evopoint Biosciences Inc.INDUSTRY | 1 | Jan 12, 2026 | clinicaltrials |
| NCT04134117 | Tisagenlecleucel In Primary CNS Lymphoma | completed | Phase 1 | 13 | Matthew J. Frigault, M.D.OTHER | 1 | Jan 9, 2026 | clinicaltrials |
| NCT04220684 | Trial Testing Safety of IL-21 NK Cells for Induction of R/R AML | completed | Phase 1 | 19 | Sumithira VasuOTHER | 1 | Jan 9, 2026 | clinicaltrials |
| NCT06095375 | Regorafenib With Temozolomide With or Without RT in MGMT-Methylated, IDH Wild-type GBM Patients(REGOMA-2) | completed | Phase 1 | 21 | Istituto Oncologico Veneto IRCCSOTHER | 1 | Jan 9, 2026 | clinicaltrials |
| NCT03042689 | Study of Regorafenib in Patients With Advanced Myeloid Malignancies | completed | Phase 1 | 16 | Massachusetts General HospitalOTHER | 1 | Jan 8, 2026 | clinicaltrials |
| NCT03290937 | Utomilumab, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Metastatic Colorectal Cancer | completed | Phase 1 | 34 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT03702725 | Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma | completed | Phase 1 | 14 | Alliance Foundation Trials, LLC.OTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT05678998 | WTX-330 in Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma | completed | Phase 1 | 25 | Werewolf Therapeutics, Inc.INDUSTRY | 1 | Jan 6, 2026 | clinicaltrials |
| NCT02709226 | Dose Escalation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma | completed | Phase 1 | 17 | National Cancer Institute (NCI)NIH | 1 | Dec 31, 2025 | clinicaltrials |
| NCT01970358 | A Phase I Study With a Personalized NeoAntigen Cancer Vaccine in Melanoma | completed | Phase 1 | 15 | Patrick Ott, MD, PhDOTHER | 1 | Dec 29, 2025 | clinicaltrials |
| NCT04045496 | A First-in-Human, Phase 1 Study of JAB-3312 in Adult Patients With Advanced Solid Tumors | completed | Phase 1 | 40 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Dec 29, 2025 | clinicaltrials |
| NCT06562673 | Intra-arterial Cisplatin Plus Rh-endostatin Combined With Systematic Chemotherapy in Osteosarcoma(IACE-OS) | completed | Phase 1 / Phase 2 | 10 | Shanghai 6th People's HospitalOTHER | 1 | Dec 29, 2025 | clinicaltrials |
| NCT01695005 | A Study of LY3039478 in Participants With Advanced Cancer | completed | Phase 1 | 247 | Eli Lilly and CompanyINDUSTRY | 6 | Dec 26, 2025 | clinicaltrials |
| NCT04474353 | Study of Tumor Treating Fields With Hypofractionated Chemoradiotherapy in Newly Diagnosed Glioblastoma | completed | Phase 1 | 12 | Stanford UniversityOTHER | 1 | Dec 26, 2025 | clinicaltrials |
| NCT05025358 | A Study of LP-118 in Patients With Advanced Tumors | completed | Phase 1 | 68 | Guangzhou Lupeng Pharmaceutical Company LTD.INDUSTRY | 1 | Dec 26, 2025 | clinicaltrials |
| NCT01658878 | An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver Cancer(CheckMate040) | completed | Phase 1 / Phase 2 | 657 | Bristol-Myers SquibbINDUSTRY | 13 | Dec 24, 2025 | clinicaltrials |
| NCT04155710 | Study of Autologous Peripheral Blood Lymphocytes in the Treatment of Patients With CLL or SLL | completed | Phase 1 | 7 | Iovance Biotherapeutics, Inc.INDUSTRY | 1 | Dec 24, 2025 | clinicaltrials |
| NCT03810807 | Study of Dacomitinib and Osimertinib for Patients With Advanced EGFR Mutant Lung Cancer | completed | Phase 1 | 22 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 23, 2025 | clinicaltrials |
| NCT05483933 | Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers | completed | Phase 1 | 86 | Shattuck Labs, Inc.INDUSTRY | 4 | Dec 23, 2025 | clinicaltrials |
| NCT06120712 | A Study of GC101 TIL in Advanced Melanoma (BZ)(MIZAR-002) | completed | Phase 1 / Phase 2 | 18 | Shanghai Juncell TherapeuticsINDUSTRY | 1 | Dec 23, 2025 | clinicaltrials |
| NCT01665794 | Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 25 | University of ChicagoOTHER | 2 | Dec 22, 2025 | clinicaltrials |
| NCT05120570 | PTCy + Sirolimus/VIC-1911 as GVHD Prophylaxis in Myeloablative PBSC Transplantation | completed | Phase 1 / Phase 2 | 16 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 22, 2025 | clinicaltrials |
| NCT01858168 | Phase I Study of Olaparib and Temozolomide for Ewings Sarcoma or Rhabdoomyosarcoma | completed | Phase 1 | 49 | Massachusetts General HospitalOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT02296918 | Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL | completed | Phase 1 | 69 | Acerta Pharma BVINDUSTRY | 1 | Dec 19, 2025 | clinicaltrials |
| NCT02473380 | Fluorescence Spectroscopy Guided Surgery(GLIOSPECT) | completed | Phase 1 | 11 | Hospices Civils de LyonOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT03573310 | A Study of JNJ-64619178, an Inhibitor of PRMT5 in Participants With Advanced Solid Tumors, NHL, and Lower Risk MDS | completed | Phase 1 | 114 | Janssen Research & Development, LLCINDUSTRY | 5 | Dec 18, 2025 | clinicaltrials |
| NCT03638167 | EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS Tumors | completed | Phase 1 | 11 | Seattle Children's HospitalOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT04082962 | Dexamethasone Implant for Retinal Detachment in Uveal Melanoma | completed | Phase 1 | 10 | Ivana K. KimOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT05342636 | A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A) | completed | Phase 1 / Phase 2 | 90 | Merck Sharp & Dohme LLCINDUSTRY | 13 | Dec 17, 2025 | clinicaltrials |
| NCT02621398 | Pembrolizumab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-IIIB Non-Small Cell Lung Cancer | completed | Phase 1 | 23 | Rutgers, The State University of New JerseyOTHER | 1 | Dec 16, 2025 | clinicaltrials |
| NCT02860676 | Extension Study of UC-961 (Cirmtuzumab) for Patients With Chronic Lymphocytic Leukemia Treated Previously With UC-961 | completed | Phase 1 | 3 | University of California, San DiegoOTHER | 1 | Dec 15, 2025 | clinicaltrials |
| NCT04580446 | HYHOPE: De-intensified Hypofractionated Radiation Therapy for HPV-associated Oropharynx Cancer | completed | Phase 1 | 24 | University of Texas Southwestern Medical CenterOTHER | 1 | Dec 15, 2025 | clinicaltrials |
| NCT06549816 | A Study of SGN-B6A in Chinese Participants With Advanced Solid Tumors | completed | Phase 1 | 6 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 1 | Dec 15, 2025 | clinicaltrials |
| NCT03310957 | Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer | completed | Phase 1 / Phase 2 | 185 | Seagen Inc.INDUSTRY | 4 | Dec 12, 2025 | clinicaltrials |
| NCT05182073 | FT576 in Subjects With Multiple Myeloma | completed | Phase 1 | 31 | Fate TherapeuticsINDUSTRY | 1 | Dec 12, 2025 | clinicaltrials |
| NCT02328014 | Acalabrutinib (ACP-196) in Combination With ACP-319, for Treatment of B-Cell Malignancies | completed | Phase 1 / Phase 2 | 40 | Acerta Pharma BVINDUSTRY | 1 | Dec 9, 2025 | clinicaltrials |
| NCT02592577 | MAGE A10ᶜ⁷⁹⁶T for Advanced NSCLC | completed | Phase 1 | 28 | AdaptimmuneINDUSTRY | 4 | Dec 9, 2025 | clinicaltrials |
| NCT07271446 | An Autologous NK/CIK Cell Product (PB101) in Combination With EGFR-TKI for Treating Lung Cancer | completed | Phase 1 | 8 | Precision Biotech Taiwan Corp.INDUSTRY | 1 | Dec 9, 2025 | clinicaltrials |
| NCT03177291 | Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC | completed | Phase 1 | 48 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 5, 2025 | clinicaltrials |
| NCT03381183 | IRX-2 Regimen and Durvalumab, for Incurable H&N Squamous Cell Carcinoma | completed | Phase 1 | 19 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 5, 2025 | clinicaltrials |
| NCT03526679 | Lenvatinib and Eribulin in Advanced Soft Tissue Sarcoma(LEADER) | completed | Phase 1 / Phase 2 | 30 | National Taiwan University HospitalOTHER | 1 | Dec 5, 2025 | clinicaltrials |
| NCT05065866 | Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy | completed | Phase 1 | 14 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT02950259 | Pre-operative IRX-2 in Early Stage Breast Cancer (ESBC) | completed | Phase 1 | 16 | Providence Health & ServicesOTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT03377361 | An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has Spread(CheckMate 9N9) | completed | Phase 1 / Phase 2 | 325 | Bristol-Myers SquibbINDUSTRY | 10 | Dec 3, 2025 | clinicaltrials |
| NCT03575013 | A Combination of Avelumab and Taxane (AVETAX) for Urothelial Cancer | completed | Phase 1 | 21 | Yousef ZakhariaOTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT02302469 | Study of Lenalidomide in Relapse/Refractory Waldenstrom Macroglobulinemia(RV-WM-0426) | completed | Phase 1 / Phase 2 | 17 | University Hospital, LilleOTHER | 1 | Nov 28, 2025 | clinicaltrials |
| NCT04116658 | First-in-Human, Phase 1b/2a Trial of a Multipeptide Therapeutic Vaccine in Patients With Progressive Glioblastoma(ROSALIE) | completed | Phase 1 / Phase 2 | 100 | EnteromeINDUSTRY | 4 | Nov 28, 2025 | clinicaltrials |
Data updated 24 days agoSource updated Jan 13, 2026source: clinicaltrials